UK-CAB 65: 21 April 2018
BHIVA BASHH feedback – Treatment as Prevention (TasP) – Edinburgh, Saturday 21 April 2018
Please note: This meeting was held place in Edinburgh, to take advantage of the BHIVA/BASHH conference.
Programme
| 09.15-09.30 | Arrival, tea and refreshments |
| 09.30-10.00 | Welcome and introductions, UK-CAB updates, company pre-meeting |
| 10.00-11.30 | Company meeting: MSD |
| 11.30-11.45 | BREAK |
| 11.45-12.45 | Conference feedback – clinical perspective – Prof. Clifford Leen, Western General Hospital |
| 12.45-14.00 | LUNCH |
| 14.00-15.30 | Treatment as/for prevention
· 2018 BHIVA Pregnancy guidelines – Angelina Namiba · TasP for Sexual reproduction health – Aicha Kallo · U=U discussion feedback – Longret Kwardem & Sunil Pant |
| 15.30-15.45 | BREAK |
| 15.45-16.30 | Conferences feedback – CROI
BHIVA/BASHH Conference community feedback Reflection and feedback of the meeting member updates |
| 16.30 | Meeting close |
Presentations from this meeting
- BHIVA BASHH Feedback, slide set 1 of 2 – Prof. Clifford Leen
- BHIVA BASHH feedback, slide set 2 0f 2
- 2018 BHIVA pregnancy guidelines feedback – Angelina Namiba
- TasP for Sexual reproduction health– Aicha Kallo
- U=U discussion feedback – Longret Kwardem
Background reading
BHIVA guidelines
BHIVA produces a number of guidelines for the clinical management of HIV. You can see all the guidelines here, including the ones that have been updated and will be presented at the BHIVA/BASHH conference.
Breast is best – presentations, debate and discussion
See paper prepared by Angelina for her session on Pregnancy guidelines.
Treatment as prevention:
Prevention access campaign:
“U=U is a simple but hugely important campaign based on a solid foundation of scientific evidence. It has already been successful in influencing public opinion, causing more people with HIV (and their friends and families) to comprehend that they can live long, healthy lives, have children, and never have to worry about passing on their infection to others.” The Lancet (November, 2017)
- The evidence for U=U (Undetectable = Untransmittable): why negligible risk is zero risk
- Treatment as prevention from Avert
Here are two videos that talk about ‘combination prevention’ from BHIVA in Liverpool last year.
CROI conference feedback:
Important themes this year included cure-related research; TB coinfection, PrEP and new antiretroviral drugs. As usual, webcasts and conference material are already online. Also, news that after more than a decade in development, the monoclonal antibody ibalizumab has been approved in the US as a treatment for multidrug resistant HIV.
Here are some CROI reports from HIV i-Base:
Financial support
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.
The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.